Lidocaine-Ketamine Versus Ketamine for Induction of Anesthesia in Septic Shock Patients

November 23, 2019 updated by: Ahmed Hasanin, Cairo University

Lidocaine-Ketamine Versus Ketamine for Induction of Anesthesia in Septic Shock Patients: a Randomized Controlled Trial

The aim of the work is to investigate the effect of using lidocaine in combination with low dose ketamine in induction of anesthesia for septic shock patients compared to normal dose of ketamine.

Study Overview

Detailed Description

Most of the drugs used for induction of anesthesia negatively impact patient hemodynamics. Thus, induction of anesthesia in shocked patients might result in deleterious hypotension. Patients with severe sepsis and septic shock frequently need surgical interventions. The best protocol for induction of anesthesia in septic shock patients is lacking.

Ketamine is an agent used for induction of anesthesia with known positive cardiovascular effects. However, these positive effects were reported in individuals with intact sympathetic nervous system. Invitro studies showed that ketamine direct action on the cardiac muscles is negative. Thus, it had been recommended that ketamine should be used with caution in hemodynamically vulnerable patients till further randomized controlled trials are present.

Lidocaine is a drug with multiple local and systemic uses. Having local anesthetic properties, lidocaine was proposed to have an anesthetic sparing effect. Lidocaine was previously reported to enhance the hypnotic effect of thiopentone, propofol, and midazolam during induction of anesthesia. Lidocaine showed a sparing effect for volatile as well as intravenous requirements for maintenance of anesthesia; thus, we hypothesize that its use as an adjuvant during induction of anesthesia in septic shock patient could provide a sparing effect for ketamine and minimize its negative circulatory sequelae.

Study Type

Interventional

Enrollment (Actual)

43

Phase

  • Phase 3

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Cairo, Egypt, 11432
        • Ahmed Mohamed Hasanin

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (ADULT, OLDER_ADULT)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Adult patients aged above 18 years
  • With septic shock
  • Scheduled for general anesthesia

Exclusion Criteria:

  • Patients under 18 years
  • Burn patients

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: TREATMENT
  • Allocation: RANDOMIZED
  • Interventional Model: PARALLEL
  • Masking: QUADRUPLE

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
ACTIVE_COMPARATOR: Ketamine group
This group will receive induction of anesthesia using ketamie full dose 1 mg/kg, midazolam 0.05 mg/Kg, and normal saline 10 mL.
This group will receive midazolam 0.05 mg/Kg
Other Names:
  • dormicum
This group will receive normal saline 10 mL
This group will receive induction of anesthesia using Ketamine 1 mg/Kg.
Other Names:
  • Ketamine hydrochloride
EXPERIMENTAL: Lidocaine-ketamine group
This group will receive induction of anesthesia using Ketamie half dose 0.5 mg/kg, midazolam 0.05 mg/Kg, and lidocaine 1 mg/Kg.
This group will receive midazolam 0.05 mg/Kg
Other Names:
  • dormicum
This group will receive induction of anesthesia using Ketamine 0.5 mg/Kg.
Other Names:
  • Ketamine hydrochloride
This group will receive lidocaince 1 mg/Kg diluted in 10 mL normal saline.
Other Names:
  • Lidocaine hydrochloride

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Mean arterial blood pressure
Time Frame: 10 minutes after induction of general anesthesia
Mean arterial blood pressure measured in mmHg
10 minutes after induction of general anesthesia

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Norepinephrine consumption
Time Frame: 10 minutes after induction of general anesthesia
The total dose of norepinephrine measured in micrograms
10 minutes after induction of general anesthesia
Heart rate
Time Frame: 10 minutes after induction of general anesthesia
Number of heart beats per minute
10 minutes after induction of general anesthesia
The number of patients who suffer from post-induction hypotension.
Time Frame: 5 minutes after induction of general anesthesia
The number of patients who suffer from decreased mean arterial pressure by 10% from the baseline reading during the first 5 minutes after induction of anesthesia
5 minutes after induction of general anesthesia
Cardiac output
Time Frame: 10 minutes after induction of general anesthesia
Volume of blood pumped by the heart in one minute measured in liters per minute
10 minutes after induction of general anesthesia
Systolic blood pressure
Time Frame: 10 minutes after induction of general anesthesia
Systolic arterial blood pressure measured in mmHg
10 minutes after induction of general anesthesia

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Study Chair: Ashraf Rady, Professor, Head of department of anesthesia, Cairo University, Egypt

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (ACTUAL)

February 20, 2019

Primary Completion (ACTUAL)

September 20, 2019

Study Completion (ACTUAL)

September 20, 2019

Study Registration Dates

First Submitted

February 15, 2019

First Submitted That Met QC Criteria

February 15, 2019

First Posted (ACTUAL)

February 19, 2019

Study Record Updates

Last Update Posted (ACTUAL)

November 26, 2019

Last Update Submitted That Met QC Criteria

November 23, 2019

Last Verified

November 1, 2019

More Information

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Septic Shock

Clinical Trials on Midazolam

3
Subscribe